Trials / Unknown
UnknownNCT05150457
Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Binacea Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and tolerability of BNA035 in order to determine the maximum tolerated dose (MTD) and Recommended Phase 2 dose (RP2D) and to evaluate the preliminary efficacy for each combination regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BNA035 | Anti-epidermal growth factor receptor (Anti-EGFR) and anti-cluster of differentiation 137 (anti-CD137) bispecific antibody |
Timeline
- Start date
- 2022-02-08
- Primary completion
- 2023-11-01
- Completion
- 2025-11-01
- First posted
- 2021-12-09
- Last updated
- 2022-09-27
Locations
3 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT05150457. Inclusion in this directory is not an endorsement.